Microbiology and Immunology

You are here

Publications

Found 81 results

Author Title [ Type

] Year

Filters: Author is Moore, John P [Clear All Filters]

Journal Article

Ringe RP, Colin P, Ozorowski G, Allen JD, Yasmeen A, Seabright GE, Lee JHyun, Antanasijevic A, Rantalainen K, Ketas T et al.. 2023. Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.. PLoS Pathog. 19(10):e1011601.

Schorcht A, Cottrell CA, Pugach P, Ringe RP, Han AX, Allen JD, van den Kerkhof TLGM, Seabright GE, Schermer EE, Ketas TJ et al.. 2022. The Glycan Hole Area of HIV-1 Envelope Trimers Contributes Prominently to the Induction of Autologous Neutralization.. J Virol. 96(1):e0155221.

Alwine J, Goodrum F, Banfield B, Bloom D, Britt WJ, Broadbent AJ, Campos SK, Casadevall A, Chan GC, Cliffe AR et al.. 2024. The harms of promoting the lab leak hypothesis for SARS-CoV-2 origins without evidence.. J Virol. 98(9):e0124024.

Dingens AS, Pratap P, Malone K, Hilton SK, Ketas T, Cottrell CA, Overbaugh J, Moore JP, Klasse PJ, Ward AB et al.. 2021. High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination.. Elife. 10

Klasse PJ, Sanders RW, Ward AB, Wilson IA, Moore JP. 2025. The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies.. Nat Rev Microbiol.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al.. 2015. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science. 349(6244):aac4223.

Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, Dodd J, Dean H, Sattentau Q, Montefiori D et al.. 2023. HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.. PLoS One. 18(10):e0293148.

Klasse PJohan, Sanders RW, Cerutti A, Moore JP. 2012. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses. 28(1):1-15.

Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP. 2010. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.. AIDS Res Hum Retroviruses. 26(4):445-58.

Nelson AN, Shen X, Vekatayogi S, Zhang S, Ozorowski G, Dennis M, Sewall LM, Milligan E, Davis D, Cross KA et al.. 2024. Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques.. Sci Immunol. 9(98):eadm7097.

Brouwer PJM, Antanasijevic A, de Gast M, Allen JD, Bijl TPL, Yasmeen A, Ravichandran R, Burger JA, Ozorowski G, Torres JL et al.. 2021. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles.. NPJ Vaccines. 6(1):24.

Klasse PJ, Nixon DF, Moore JP. 2021. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.. Sci Adv. 7(12)

Pugach P, Ray N, Klasse PJohan, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP. 2009. Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.. Virology. 387(2):296-302.

Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW et al.. 2015. Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.. J Virol. 89(23):12189-210.

Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, Naaijkens BA, David KB, Le Douce V, Deelder AM, Kang K et al.. 2010. Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function.. Virology. 401(2):236-47.

Burton DR, Hessell AJ, Keele BF, Klasse PJohan, Ketas TA, Moldt B, D Dunlop C, Poignard P, Doyle LA, Cavacini L et al.. 2011. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.. Proc Natl Acad Sci U S A. 108(27):11181-6.

Prabhu M, Yang YJ, Johnston CD, Murphy EA, Ketas TJ, Díaz-Tapia R, Jurkiewicz M, Racine-Brzostek S, Mohammed I, Sukhu AC et al.. 2023. Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant persons.. Am J Obstet Gynecol MFM. 5(2):100796.

Behrens A-J, Harvey DJ, Milne E, Cupo A, Kumar A, Zitzmann N, Struwe WB, Moore JP, Crispin M. 2017. Molecular Architecture of the Cleavage-Dependent Mannose Patch on a Soluble HIV-1 Envelope Glycoprotein Trimer.. J Virol. 91(2)

Berro R, Klasse PJohan, Lascano D, Flegler A, Nagashima KA, Sanders RW, Sakmar TP, Hope TJ, Moore JP. 2011. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.. J Virol. 85(16):8227-40.

Sanders RW, Moore JP. 2017. Native-like Env trimers as a platform for HIV-1 vaccine design.. Immunol Rev. 275(1):161-182.

Pugach P, Ketas TJ, Michael E, Moore JP. 2008. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.. Virology. 377(2):401-7.

Forbes CJ, Lowry D, Geer L, Veazey RS, Shattock RJ, Klasse PJohan, Mitchnick M, Goldman L, Doyle LA, Muldoon BCO et al.. 2011. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.. J Control Release. 156(2):161-9.

Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP. 2008. N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.. Virology. 372(1):187-200.

Van Voorhis WC, Adams JH, Adelfio R, Ahyong V, Akabas MH, Alano P, Alday A, Resto YAlemán, Alsibaee A, Alzualde A et al.. 2016. Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond.. PLoS Pathog. 12(7):e1005763.

Moore JP, Kuritzkes DR. 2009. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.. Curr Opin HIV AIDS. 4(2):118-24.